Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Results of Operations and Financial Condition

Item2.02.Results of Operations and Financial
Condition

On May9, 2017, Axsome Therapeutics,Inc. (the Company) issued a
press release announcing its financial results for the three
months ended March31, 2017 and an update on the Companys
operations. The Company is furnishing a copy of the press
release, which is attached hereto as Exhibit99.1.

In accordance with General Instruction B.2 of Form8-K, the
information included in Item 2.02 of this Current Report on
Form8-K (including Exhibit99.1 hereto), shall not be deemed filed
for the purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference into any filing made by the Company under the
Exchange Act or Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such a
filing.

Item8.01.Other Events.

On May8, 2017, the Company issued a press release announcing that
it had received, from the U.S. Food and Drug Administration, Fast
Track designation for one of the Companys lead product
candidates, AXS-05, for the treatment of Alzheimers disease
agitation.

The full text of the press release is filed as Exhibit99.2 hereto
and is incorporated herein by reference.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session 00.00 at 4.20 with 2,444,453 shares trading hands.